Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: Novel HSV-2 vaccine/therapy precursors

Theoretical Biology and Medical Modelling

Volumn 8, Issue 1, 2011, Pages

  Wayengera, Misaki ^a  

^a MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); DNA VIRUSES; ESCHERICHIA COLI; FLAVOBACTERIUM; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 2; PLANOMICROBIUM OKEANOKOITES; SIMPLEXVIRUS;

DEOXYRIBONUCLEASE; HERPES SIMPLEX VACCINE; VIRUS DNA; ZINC FINGER PROTEIN;

ARTICLE; BASE PAIRING; BIOLOGICAL MODEL; ENZYME SPECIFICITY; GENE VECTOR; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GENETICS; GENOTYPE; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; VIRUS GENOME;

BASE PAIRING; BASE SEQUENCE; DEOXYRIBONUCLEASES; DNA, VIRAL; GENETIC VECTORS; GENOME, VIRAL; GENOTYPE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; MODELS, GENETIC; RECOMBINATION, GENETIC; SUBSTRATE SPECIFICITY; TRANSDUCTION, GENETIC; ZINC FINGERS;

EID: 79959471971     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-8-23     Document Type: Article

References (62)

1. Genital herpes simplex virus infections. L Corey HG Adams ZA Brown KK Holmes, Ann Intern Med 1983 98 958 972 6344712
2. Seroepidemiological and sociological patterns of herpes simplex virus infection in the world. AJ Nahmias FK Lee S Beckman-Nahmias, Scand J Infect Dis Suppl 1990 69 19 36 2175939 (Pubitemid 20333084)
3. Evolution of recurrent herpes simplex lesions. An immunohistologic study. AL Cunningham RR Turner AC Miller MF Para TC Merigan, J Clin Invest 1985 75 1 226 233 10.1172/JCI111678 3880773 (Pubitemid 15171242)
4. Reinfection is an uncommonoccurrence in patients with symptomatic recurrent genital herpes. OW Schmidt KH Fife L Corey, J Infect Dis 1984 149 645 646 10.1093/infdis/149.4.645 6327838 (Pubitemid 14139054)
5. Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. AD Lakeman AJ Nahmias RJ Whitley, Sex Transm Dis 1986 13 61 66 10.1097/00007435-198604000-00001 3012807 (Pubitemid 17212094)
6. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. A Wald L Corey R Cone A Hobson G Davis J Zeh, J Clin Invest 1997 99 1092 1097 10.1172/JCI119237 9062368 (Pubitemid 27123647)
7. Risk factors for the sexual transmission of genital herpes. GJ Mertz J Benedetti R Ashley SA Selke L Corey, Ann Intern Med 1992 116 197 202 1309413
8. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. M del Mar Pujades Rodriguez A Obasi F Mosha J Todd D Brown J Changalucha D Mabey D Ross H Grosskurth R Hayes, AIDS 2002 16 3 451 462 10.1097/00002030-200202150-00018 11834958 (Pubitemid 34165378)
9. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. RH Gray MJ Wawer R Brookmeyer NK Sewankambo D Serwadda F Wabwire-Mangen T Lutalo X Li T vanCott TC Quinn, Lancet 2001 357 9263 1149 1153 10.1016/S0140-6736(00)04331-2 11323041 (Pubitemid 32378686)
10. Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. A Calistri C Parolin M Pizzato P Calvi I Giaretta G Palu, J Acquir Immune Defic Syndr 1999 21 2 90 98 10360799 (Pubitemid 29250071)
11. Herpes simplex virus type 2. WHO UNAIDS, Programmatic and research priorities in developing countries 2001
12. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Nagot A Ouedraogo V Foulongne I Konate HA Weiss L Vergne MC Defer D Djagbare A Sanon JB Andonaba P Becquart M Segondy R Vallo A Sawadogo P Van de Perre P Mayaud ANRS 1285 Study Group, N Engl J Med 2007 356 790 799 10.1056/NEJMoa062607 17314338 (Pubitemid 46294611)
13. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo controlled, cross-over trial. JM Baeten LB Strick A Lucchetti WL Whittington J Sanchez RW Coombs A Magaret A Wald L Corey C Celum, J Infect Dis 2008 198 1804 1808 10.1086/593214 18928378
14. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebocontrolled trial. C Celum A Wald J Hughes J Sanchez S Reid S Delany-Moretlwe F Cowan M Casapia A Ortiz J Fuchs S Buchbinder S Zwerski S Rose J Wang L Corey HPTN 039 Proctocol Team, Lancet 2008 371 9630 2109 2119 10.1016/S0140-6736(08)60920-4 18572080 (Pubitemid 351902179)
15. Impact of Antivirals and Emergence of Drug Resistance: HSV-2 Epidemic Control. HB Gershengorn SM Blower, AIDS Patient Care and STDs 2000 14 3 133 142 10.1089/108729100317911 10763542 (Pubitemid 30185384)
16. Current treatment options to prevent perinatal transmission of herpes simplex virus. DT Leung SL Sacks, Expert Opin Pharmacother 2003 4 10 1809 1819 10.1517/14656566.4.10.1809 14521490 (Pubitemid 37322365)
17. Update on antiviral therapy for genital herpes infection. TA Geers CM Isada, Cleve lin J Med 2000 67 8 567 573 (Pubitemid 30618548)
18. Contemporary approaches to vaccination against herpes simplex virus. RL Burke, Curr Top Microbiol Immunol 1992 179 137 158 1499347
19. Prospects for vaccination against herpes simplex virus. RJ Whitley, Pediatr Ann 1993 22 726 732 8139874
20. Herpes simplex virus vaccines as immunotherapeutic agents. LR Stanberry, Trends Microbiol 1995 3 244 247 10.1016/S0966-842X(00)88933-7 7648034
21. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. SE Straus L Corey RL Burke B Savarese G Barnum PR Krause RG Kost JL Meier R Sekulovich SF Adair LC Dekker, Lancet 1994 343 8911 1460 1463 10.1016/S0140-6736(94)92581-X 7911177 (Pubitemid 24176334)
22. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group. L Corey AG Langenberg R Ashley RE Sekulovich AE Izu JM Douglas Jr HH Handsfield T Warren L Marr S Tyring R DiCarlo AA Adimora P Leone CL Dekker RL Burke WP Leong SE Straus, JAMA 1999 282 4 331 340 10.1001/jama.282.4.331 10432030 (Pubitemid 29350487)
23. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. G Casanova R Cancela L Alonzo R Benuto C Magana Mdel DR Hurley E Fishbein C Lara T Gonzalez R Ponce JW Burnett GJ Calton, Cutis 2002 70 4 235 239 12403316 (Pubitemid 41757449)
24. A growth and latency defective herpes simplex virus type 2 mutant (ICP10PK) has prophylactic and therapeutic protective activity in guinea pigs. M Wachsman M Kulka CC Smith L Aurelian, Vaccine 2001 19 1879 1890 10.1016/S0264-410X(00)00446-1 11228357 (Pubitemid 32178335)
25. Growth-compromised HSV-2 vector RR protects from N-methyl-D-aspartate- induced neuronal degeneration through redundant activation of the MEK/ERK and PI3-K/Akt survival pathways, either one of which overrides apoptotic cascades. JM Laing EK Golembewski SQ Wales J Liu SM Jafri PJ Yarowsky L Aurelian, Journal of Neuroscience Research 2008 86 2 378 391 10.1002/jnr.21486 17893911 (Pubitemid 351196743)
26. Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. DJ McGeoch A Dolan S Donald DHK Brauer, Nucleic Acids Res 1986 14 1727 1745 10.1093/nar/14.4.1727 3005980
27. The genome sequence of herpes simplex virus type 2: The genome sequence of herpes simplex virus type 2. A Dolan FE Jamieson C Cunningham BC Barnett DJ McGeoch, J Virol 1998 72 3 2010 2021 9499055
28. The structure and isomerization of herpes simplex virus genomes. B Roizman, Cell 1979 16 481 494 10.1016/0092-8674(79)90023-0 222462 (Pubitemid 9140453)
29. Herpes simplex virus 1 g134.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. J Chou B Roizman, Proc Natl Acad Sci USA 1994 91 5247 5251 10.1073/pnas.91.12.5247 8202476 (Pubitemid 24174303)
30. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. KE Johnson B Song DM Knipe, Virology 2008 374 2 487 494 10.1016/j.virol.2008.01.001 18279905
31. Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: inherent potential for biosynthetic versus live recombinant microbicides. M Wayengera H Kajumbula W Byarugaba, Theor Biol Med Model 2008 5 18 10.1186/1742-4682-5-18 18687114
32. Diverting primary HIV entry and replication to vaginal commensal lactobacillus expressing R-M nucleic enzymatic peptides with potent activity at cleaving proviral DNA as a novel HIV live microbicide strategy. M Wayengera, Microbicide- New Delhi, India 2008 Feb 23-28: Abs-10
33. Preparing for a Phase 1 Preclinical trial of VRX-SMR: a Lentiviral Vector transduced with restriction enzymes cleaving HIV proviral DNA as a therapeutic vaccine: Opportunities and Challenges. M Wayengera, Vaccine Congress -Amsterdam, Netherlands 2007 Dec 9-11: 24OR
34. ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. JD Sander ML Maeder D Reyon DF Voytas JK Joung D Dobbs, Nucl Acids Res 2010 38 462 468 10.1093/nar/gkq319 20435679
35. Zinc finger tools: custom DNA-binding domains for transcription factors and nucleases. JG Mandell CF Barbas, Nucl Acids Res 2006 34 SI 516 W523 16845061
36. Insights into the molecular recognition of the 5 '-GNN-3 ' family of DNA sequences by zinc finger domains. B Dreier DJ Segal CF Barbas, J Mol Biol 2000 303 4 489 502 10.1006/jmbi.2000.4133 11054286
37. Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells. S Grosse N Huot C Mahiet S Arnould S Barradeau DL Clerre I Chion-Sotinel C Jacqmarcq B Chapellier A Ergani C Desseaux F Cédrone E Conseiller F Pques M Labetoulle J Smith, Mol Ther 2011 19 4 694 702 10.1038/mt.2010.302 21224832
38. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Y-G Kim J Cha S Chandrasegaran, Proc Natl Acad Sci USA 1995 93 1156 1160 (Pubitemid 26052857)
39. Comparison of Zinc Finger Nucleases for use in Gene Targeting in Mammalian Cells. SM Pruett-Miller JP Connelly ML Maeder JK Joung MH Porteus, Mol Ther 2008 16 707 717 10.1038/mt.2008.20 18334988 (Pubitemid 351426172)
40. Herpesvirus vectors for therapy of brain tumors. KA Cassady JN Parker, Open Virol J 2010 4 103 108 20811578
41. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. X Liu E Broberg D Watanabe T Dudek N Deluca DM Knipe, Vaccine 2009 27 21 2760 2767 10.1016/j.vaccine.2009.03.003 19428888
42. Replication-defective viruses as vaccines and vaccine vectors. T Dudek DM Knipe, Virology 2006 344 1 230 239 10.1016/j.virol.2005.09.020 16364753 (Pubitemid 41814465)
43. A gene delivery/recall system for neurons which utilizes ribonucleotide reductase-negative herpes simplex viruses. JY Chang JM Johnson Jr PD Olivo, Virology 1991 185 1 437 440 10.1016/0042-6822(91)90794-C 1656596
44. Engineering Herpes Simplex. J Glorioso WF Goins MC Schmidt T Oligino DM Krisky PC Marconi PC Cavalcoli R Ramakrishnan PL Poliani DJ Fink, Advances in Pharmacology 1997 40 103 136 9217925
45. Herpes Simplex Virus as a Gene-Delivery Vector for the Central Nervous System. JC Glorioso AM Bender WF Goins N DeLuca DJ Fink, Viral Vectors 1995 1 23
46. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. DJ Goldstein SK Weller, J Virol 1988 62 1 196 205 2824847 (Pubitemid 18050809)
47. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Y Hoshino SK Dalai K Wang L Pesnicak TY Lau DM Knipe JI Cohen SE Straus, J Virol 2005 79 410 418 10.1128/JVI.79.1.410-418.2005 15596834 (Pubitemid 39648394)
48. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. CS McLean R Jennings DN Challanain AC Minson I Duncan ME Boursnell SC Inglis, J Infect Dis 1994 170 1100 1109 10.1093/infdis/170.5.1100 7963701 (Pubitemid 24328611)
49. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons involving activation of the ERK survival pathway and upregulation of the antiapoptotic protein Bag-1. D Perkins EF Pereira L Aurelian, J Virol 2003 77 1292 1305 10.1128/JVI.77.2. 1292-1305.2003 12502846 (Pubitemid 36055552)
50. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. DJ Goldstein SK Weller, Virology 1988 166 1 41 51 10.1016/0042-6822(88)90144-4 2842955
51. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. CC Smith J Nelson L Aurelian M Gober BB Goswami, J Virol 2000 74 10417 10429 10.1128/JVI.74.22.10417-10429.2000 11044086
52. AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J Zhu L Aurelian, Virology 1997 231 301 312 10.1006/viro.1997.8522 9168892 (Pubitemid 27244196)
53. Stress upregulates neuronal expression of the HSV-2 large subunit of ribonucleotide reductase (R1; ICP10) by activating AP-1. MD Gober SQ Wales JC Hunter BK Sharma L Aurelian, J Neurovirol 2005 11 329 36 10.1080/ 13550280591002423 16162476 (Pubitemid 41614512)
54. Genome editing with engineered zinc finger nucleases. FD Urnov EJ Rebar MC Holmes HS Zhang PD Gregory, Nat Rev Genet 2010 11 9 636 646 S 10.1038/nrg2842 20717154
55. Gene targeting using zinc finger nucleases. MH Porteus D Carroll, Nat Biotechnol 2005 23 8 967 973 10.1038/nbt1125 16082368 (Pubitemid 41114030)
56. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. S Durai M Mani K Kandavelou J Wu MH Porteus S Chandrasegaran, Nucleic Acids Res 2005 33 18 5978 5990 10.1093/nar/gki912 16251401 (Pubitemid 41742617)
57. Zinc-finger nucleases: the next generation emerges. T Cathomen JK Joung, Mol Ther 2008 16 7 1200 1207 10.1038/mt.2008.114 18545224 (Pubitemid 351866050)
58. Attenuation of HIV-1 Replication in Primary Human Cells with a Designed Zinc Finger Transcription Factor. DJ Segal J Goncalves SR Eberhardy CH Swan BE Torbett X Li CF Barbas, J Biochem 2004 279 15 14509 14519 (Pubitemid 38618838)
59. Inhibition of Human Immunodeficiency Virus Type 1 Replication with Artificial Transcription Factors Targeting the Highly Conserved Primer-Binding Site. SR Eberhardy J Goncalves S Coelho DJ Segal B Berkhout CF Barbas, J Virol 2006 80 6 2873 2883 10.1128/JVI.80.6.2873-2883.2006 16501096 (Pubitemid 43346382)
60. Isolation of restriction endonuclease site deletion mutants of herpes simplex virus. SM Brown J Harland JH Subak-Sharpe, J Gen Virol 1984 65 6 1053 1068 10.1099/0022-1317-65-6-1053 6327891 (Pubitemid 14106104)
61. Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs. TJ Cradick K Keck S Bradshaw AC Jamieson AP McCaffrey, Mol Ther 2010 18 5 947 954 10.1038/mt.2010.20 20160705
62. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Y Doyon TD Vo MC Mendel SG Greenberg J Wang DF Xia JC Miller FD Urnov PD Gregory MC Holmes, Nat Methods 2011 8 1 74 79 10.1038/nmeth.1539 21131970